The pharmaceutical sector faced headwinds in July as political pressure from Trump's drug pricing ultimatum and broader market volatility weighed on most pharma stocks, creating a challenging environment for the industry overall.
Asymmetric Healthcare Portfolio: up 1.46% in…
The pharmaceutical sector faced headwinds in July as political pressure from Trump's drug pricing ultimatum and broader market volatility weighed on most pharma stocks, creating a challenging environment for the industry overall.